Hello.
Welcome back to Invested Early.
An Nvidia-backed drug developer raised $150 million on Wednesday night and closed its first day on the Nasdaq 18% above its IPO price. FMC, an S&P 500 member until last year, cut its third-quarter revenue forecast from at least $840 million to as little as $65 million and lost 30% of its value. And the Russell 2000 gained 1.38% on a day the Nasdaq finished flat, because long-term Treasury yields fell despite the hottest wholesale inflation print in four years.
Here's what's inside today:
🧾 What a company's debt tells you before its stock does
🧬 The AI drug company that priced at $16 and closed at $18.91
🌐 Six stocks whose web traffic doubled in a year
📈 Top gainers (and biggest losers) from Thursday's session
This is not financial advice. Always do your own research. Past performance doesn't guarantee future results.
Sponsored by Guardian
Apple Ran 7,537% on a Claim This Size
The last "bigger than anything before it" claim that held up belonged to the iPhone.
Apple went on to run as high as 7,537% in the years after.
Elon is making a similar claim about a device built inside Tesla, expected to be revealed Sept 21.
A free briefing names 3 tickers positioned around it, plus a bonus 4th pick.
Read the Debt Before the Stock
Thursday produced four small-cap stories, and every one was a credit story first.
CoreWeave sold $1.25 billion of 9.625% notes at par in June. This week those bonds yielded close to 15%, about 11 points over Treasuries, and the selling spread to every small cap that supplies power, chips or servers to AI data centers. The stock market read the bond market's verdict a day late.
It happened three more times on Thursday, at smaller scale:
FMC carries $4.28 billion of debt against an $874 million market cap. Thursday's release said the company expects to meet its covenants at September 30 and will ask its banks for more room next year. That sentence is why the stock fell 30% instead of 15%.
Hain Celestial disclosed in an 8-K that it missed an October 12 lender deadline tied to a $323 million asset sale. The stock lost half its value before Bloomberg reported, after the close, that the company is weighing Chapter 11.
The RealReal replaced 13% notes with a cheaper term loan and rose 16%. Same signal, opposite direction.
Four things to check before buying a levered small cap:
Debt against market cap. At four times the equity, the lenders decide the outcome.
Covenant language in the latest 10-Q. "Amendment," "waiver" and "shall not be tested" mean the company has already needed more room once.
Where the bonds trade. Below 80 cents on the dollar, the market is pricing a restructuring.
The next maturity. A refinancing can move a stock as much as an earnings report.
Stock is the last claim on a company's cash. The claims ahead of it are public, and they usually move first.
The AI Drug Company That Priced at $16 and Closed at $18.91
Iambic Therapeutics raised $150 million in its IPO on Wednesday night and began trading Thursday on the Nasdaq under IAM. It opened at $16.15, touched $19.70 and closed at $18.91, up 18% from the offer price, a market cap of roughly $896 million.
The news: Iambic sold 9.375 million shares at $16, the midpoint of its range. What the company brings public, per its prospectus:
IAM1363, an oral HER2 inhibitor that crosses the blood-brain barrier, in a Phase 1/1b trial across HER2-altered solid tumors. Interim data: a 23% confirmed response rate, with responses in 9 of 22 patients whose cancer had reached the brain.
A design platform that pairs its own AI models with robotic labs synthesizing hundreds of compounds a week.
Partnerships with AbbVie, Takeda, Lundbeck and Revolution Medicines; collaboration revenue was $12.8 million in the first half of 2026.
$207.9 million in cash at June 30, before the IPO.
Why it matters: Nvidia was a Series B investor, ARK and Stanley Druckenmiller's Duquesne indicated interest in up to $60 million of the deal, and 25 biotechs have priced IPOs in 2026 after an anemic 2025. The window is open, and it opened on a day the public AI infrastructure names were being sold. Iambic says the money lasts into or through the fourth quarter of 2028, which puts the registrational trial it plans for 2027 inside the runway.
The honest risk: The lead drug is in Phase 1. The company lost $50.1 million in the first half of the year, and the 180-day insider lockup expires in April. A first-day close is a price set by a $150 million float in a two-million-share session; it says little about where the stock trades once the lockup lifts and the trial reads out. Watch the HER2 data, and size the position for a Phase 1 asset.
Six Stocks Whose Web Traffic Doubled in a Year
Our partners at AltIndex screened a year of web-traffic data for the fastest-growing companies and found six with visits up more than 100% between September 2025 and September 2026: SharkNinja (+424%), Visa (+252%), La-Z-Boy (+162%), Cloudflare (+139%), IMAX (+122%) and Tapestry (+103%).
The useful part is the pairing. Each traffic figure sits next to the stock's 12-month return and its AI Score, so you can see where attention has turned into results (Cloudflare: 36% revenue growth, score 71) and where it hasn't (La-Z-Boy: traffic up 162%, stock down 8%, score 43). Traffic updates monthly; earnings come four times a year. For a small cap on your watchlist, the gap between the two is the edge.
🎢 The Small-Cap Scoreboard
Here's where Thursday's biggest moves landed. Two medtech catalysts and a pre-announced beat led the gainers, while a crypto treasury, a lidar maker and a spectrum play filled the losers side.
🟢 Yesterday’s biggest gainers
Symbol | Company | Price | Change | Market Cap | 52-Wk |
|---|---|---|---|---|---|
Better Home & Finance | $10.76 | +32.5% | $204M | -82% | |
Verastem | $9.23 | +19.7% | $1.12B | -2% | |
NeurAxis | $7.74 | +18.5% | $97M | +132% | |
The RealReal | $10.54 | +15.8% | $1.28B | 0% | |
Dream Finders Homes | $8.44 | +13.8% | $766M | -65% |
🔴 Yesterday’s biggest losers
Symbol | Company | Price | Change | Market Cap | 52-Wk |
|---|---|---|---|---|---|
Hain Celestial | $0.28 | -51.1% | $26M | -80% | |
FMC Corporation | $5.62 | -30.5% | $874M | -81% | |
WISeSat.Space | $3.21 | -17.3% | $62M | N/A | |
ManpowerGroup | $43.74 | -15.8% | $2.03B | +15% | |
Penguin Solutions | $61.86 | -8.5% | $3.17B | +173% |
Better Home & Finance led after former X CEO Linda Yaccarino joined its board, and mortgage lenders and homebuilders rallied as the 10-year yield fell 10 basis points to 5.09%. Verastem followed through on Wednesday's pancreatic cancer data and closed above the $8 price of its $250 million offering. NeurAxis added 26 million covered lives under a national insurer's new policy.
On the loser side, Hain Celestial and FMC are covered above. WISeSat.Space, in last week's gainers table at $5.51, fell a third straight session. ManpowerGroup dropped on in-line results and a weak fourth-quarter outlook, and Penguin Solutions fell a second day with the AI hardware names.
(Data: Yahoo Finance.)
🫡 See You Soon
Thursday brought an AI drug developer that closed 18% above its IPO price, an agricultural chemicals company that cut its revenue forecast by 90% and asked its banks for room, and a natural-foods company that lost half its value on a missed lender deadline. In all three, the credit market had the first word.
We'll keep showing you both sides.
We'll be back soon. Watching a name we should cover? Hit reply and tell us.
Cheers,
— Brandon & Blake of Invested Inc.
What did you think of today's edition?
ADVERTISING DISCLOSURES: 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.
2) This email is a paid advertisement by Guardian and does not constitute investment advice. Invested Inc. has been compensated by Guardian for the distribution of this profile and related marketing materials. We have not performed due diligence on the company and the information provided is for informational purposes only. We are not a registered investment advisor or broker-dealer.
Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.
The information provided in Invested Early is for informational and educational purposes only and should not be construed as financial advice, investment advice, or a recommendation to buy or sell any securities. Stocks & Income is not a registered investment advisor, broker-dealer, or licensed financial planner. Always do your own research and consult with a licensed financial advisor before making any investment decisions. We may hold positions in or receive compensation from the companies or products mentioned. Disclosures will be made where applicable.
Invested Early, Stocks & Income, AltIndex, Finance Wrapped, The Chain, and Future Funders are all owned by Invested, Inc.